Literature DB >> 8337736

Efficacy of ivermectin in the treatment of concomitant Mansonella perstans infections in onchocerciasis patients.

H Schulz-Key1, W Albrecht, C Heuschkel, P T Soboslay, M Banla, H Görgen.   

Abstract

As part of an ivermectin dose-ranging study of onchocerciasis patients in Togo, 55 onchocerciasis patients with concomitant mansonelliasis received single oral doses either of ivermectin (100 to 200 micrograms/kg body weight) or placebo. As expected, Onchocerca volvulus microfilariae in the skin were greatly reduced in number soon after drug treatment, but microfilariae of Mansonella perstans reacted differently. Microfilarial densities of M. perstans were assessed with a filtration technique both before, and 4 times after, treatment. In untreated patients microfilarial densities were stable until the end of the study at 6 months. In patients receiving ivermectin, microfilarial densities dropped on average to less than 60% of the pre-treatment level and remained there until the final post-treatment examination. This partial reduction was probably not caused by a microfilaricidal effect of ivermectin, but rather by an altered distribution of microfilariae in the peripheral blood and in a suspected microfilarial reservoir.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337736     DOI: 10.1016/0035-9203(93)90504-j

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

1.  The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.

Authors:  P T Soboslay; S M Geiger; N Weiss; M Banla; C G Lüder; C M Dreweck; E Batchassi; B A Boatin; A Stadler; H Schulz-Key
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

2.  Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.

Authors:  C S Mai; D M Hamm; M Banla; A Agossou; H Schulz-Key; C Heuschkel; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  A randomized trial of doxycycline for Mansonella perstans infection.

Authors:  Yaya I Coulibaly; Benoit Dembele; Abdallah A Diallo; Ettie M Lipner; Salif S Doumbia; Siaka Y Coulibaly; Siaka Konate; Dapa A Diallo; Daniel Yalcouye; Joseph Kubofcik; Ogobara K Doumbo; Abdel K Traore; Adama D Keita; Michael P Fay; Sekou F Traore; Thomas B Nutman; Amy D Klion
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

4.  Update on the distribution of Mansonella perstans in the southern part of Cameroon: influence of ecological factors and mass drug administration with ivermectin.

Authors:  Samuel Wanji; Dizzle Bita Tayong; Laura E Layland; Fabrice R Datchoua Poutcheu; Winston Patrick Chounna Ndongmo; Jonas Arnaud Kengne-Ouafo; Manuel Ritter; Nathalie Amvongo-Adjia; Fanny Fri Fombad; Charity Nya Njeshi; Armand Seraphin Nkwescheu; Peter A Enyong; Achim Hoerauf
Journal:  Parasit Vectors       Date:  2016-05-31       Impact factor: 3.876

5.  A Systematic Review of the Epidemiology of Mansonelliasis.

Authors:  Barbara L Downes; Kathryn H Jacobsen
Journal:  Afr J Infect Dis       Date:  2010

6.  Mansonella perstans, Onchocerca volvulus and Strongyloides stercoralis infections in rural populations in central and southern Togo.

Authors:  Francois Korbmacher; Kossi Komlan; Richard G Gantin; Wiyao P Poutouli; Koffi Padjoudoum; Potchoziou Karabou; Peter T Soboslay; Carsten Köhler
Journal:  Parasite Epidemiol Control       Date:  2018-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.